CO5140097A1 - Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agnetes anticancerigenos - Google Patents
Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agnetes anticancerigenosInfo
- Publication number
- CO5140097A1 CO5140097A1 CO00008430A CO00008430A CO5140097A1 CO 5140097 A1 CO5140097 A1 CO 5140097A1 CO 00008430 A CO00008430 A CO 00008430A CO 00008430 A CO00008430 A CO 00008430A CO 5140097 A1 CO5140097 A1 CO 5140097A1
- Authority
- CO
- Colombia
- Prior art keywords
- cr13r14
- aryl
- groups
- substituents
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Un compuesto de fórmula<EMI FILE="00008430_1" ID="1" IMF=JPEG >o una sal o solvato farmacéuticamente aceptable del mismo, en la que la línea de puntos indica un segundo enlace opcional que une C-3 y C-4 del anillo quinolin-2-ona; R1 se selecciona entre H, alquilo C1-C10, -(CR13R14)qC(O)R12, -(CR13R14)qC(O)OR15, -(CR13C14)qOR12, -(CR13R14)qCSO2R15, -(CR13R14)t(cicloalquilo C3-C10), -(CR13R14)t(arilo C6-C10) y -(CR13R14)t(heterociclo de 4 a 10 miembros), estando dichos grupos R1 cicloalquilo, arilo y heterocíclico opcionalmente condensados con un grupo arilo C6-C10, un grupo cíclico saturado C5-C8, o un grupo heterocíclico de 4 a 10 miembros; y estando los grupos anteriores R1, excepto H, pero incluyendo cualquier anillo condensado de los citados más arriba, sustituidos con 1 a 4 grupos R6; R2 es halógeno, ciano, -C(O)OR15, o un grupo seleccionado de los sustituyentes proporcionados en la definición de R12; cada R3, R4, R5, R6, y R7 se selecciona independientemente de H, alquilo C1-C10, alquenilo C2-C10, alquinilo C2-C10, halógeno, ciano, nitro, trifluorometilo, trifluorometoxi, azido, -OR12, -C(O)R12, -C(O)OR12, -NR13C(O)OR15, -OC(O)R12, -NR13S02R15, -SO2NR12R13, -NR13C(O)R12, -C(O)NR12R13, -NR12R13, -CH=NOR12, -S(O)jR12 siendo j un número entero de 0 a 2, -(CR13R14)t(arilo C6-C10), -(CR13R14)t(heterociclo de 4-10 miembros),(CR13R14)t(cicloalquilo C3-C10), y -(CR13R14)tC=CR16; y estando los restos cicloalquilo, arilo y heterocíclico de los grupos anteriores opcionalmente condensados con un grupo arilo C6-C10, un grupo cíclico saturado C5-C8, o un grupo heterocíclico de 4 a 10 miembros; y estando dichos grupos alquilo, alquenilo, cicloalquilo, arilo y heterocíclico opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados de halógeno, ciano, nitro, trifluorometilo, trifluorometoxi, azido, -NR13SO2R15, -SO2NR12R13, -C(O)R12, -C(O)OR12, -OC(O)R12,- 2 --NR13C(O)OR15, -NR13C(O)R12, -C(0)NR12R13, -NR12R13, -OR12, alquilo C1-C10, alquenilo C2-C10, alquinilo C2-C10, -(CR13R14)t(arilo C6-C10), y -(CR13R14)t(heterociclo de 4-10 miembros); Z es un grupo heterocíclico aromático de 4-10 miembros, sustituido con 1 a 4 sustituyentes R6; R8 es H, -OR12, -OC(0)R12, -NR12R13, -N=CR12R13, -NR12C(O)R13, ciano, -C(O)OR13, -SR12 o -(CR13R14)t(heterociclo de 4 a 10 miembros), estando dichos grupos R8 heterocíclicos sustituidos con 1 a 4 grupos R6; R9 es -(CR13R14)t(imidazolilo) o - (CR13R14)t(piridinilo), estando dicho resto imidazolilo o piridinilo sustituido con 1 ó 2 sustituyentes R6; cada R12 se selecciona independientemente de H, alquilo C1-C10, -(CR13R14)t(cicloalquilo C3-C10), -(CR13R14)t(arilo C6-C10), y -(CR13R14)t(heterociclo de 4-10 miembros); estando dichos grupos cicloalquilo, arilo, heterocíclico R12 opcionalmente condensados con un grupo arilo C6-C10, un grupo cíclico saturado C5-C8, o un grupo heterocíclico de 4 a 10 miembros; y estando los anteriores sustituyentes R12, exceptuando H pero incluyendo cualquier anillo opcionalmente condensado, opcionalmente sustituidos con 1 a 3 sustituyentes independientemente seleccionados de halógeno, ciano, nitro, trifluorometilo, trifluorometoxi, azido, -C(O)R13, -C(O)OR13, -OC(O)R13, -NR13C(O)R14, -C(O)NR13R14, -NR13R14, hidroxi, alquilo C1-C6, alcoxi C1-C6; cada t es independientemente un número entero de 0 a 5 y cada q es independientemente un número entero de 1 a 5; cada R13 y R14 es independientemente H o alquilo C1-C6, y estando R13 y R14 en la forma - (CR13R14)q o -(CR13R14)t estando cada uno independientemente definido para cada iteración de q o t superior a 1; R15 se selecciona de los sustituyentes proporcionados en la definición de R12 excepto que R15 no es H; R16 se selecciona de la lista de sustituyentes proporcionados en la definición de R12 y -SiR17R18R19; y, R17, R18 y R19 se seleccionan cada uno independientemente de los sustituyentes proporcionados en la definición de R12 excepto que al menos uno de R17, R18 y R19 no es H.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11970299P | 1999-02-11 | 1999-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5140097A1 true CO5140097A1 (es) | 2002-03-22 |
Family
ID=22385869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00008430A CO5140097A1 (es) | 1999-02-11 | 2000-02-09 | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agnetes anticancerigenos |
Country Status (39)
Country | Link |
---|---|
US (3) | US6258824B1 (es) |
EP (1) | EP1150973B1 (es) |
JP (3) | JP4090200B2 (es) |
KR (1) | KR20010102073A (es) |
CN (1) | CN1340051A (es) |
AP (1) | AP2001002241A0 (es) |
AR (1) | AR028985A1 (es) |
AT (1) | ATE297916T1 (es) |
AU (1) | AU2124800A (es) |
BG (1) | BG105860A (es) |
BR (1) | BR0008202A (es) |
CA (1) | CA2362394C (es) |
CO (1) | CO5140097A1 (es) |
CZ (1) | CZ20012910A3 (es) |
DE (1) | DE60020812T2 (es) |
DZ (1) | DZ3009A1 (es) |
EA (1) | EA200100766A1 (es) |
EE (1) | EE200100425A (es) |
ES (1) | ES2243228T3 (es) |
GT (1) | GT200000014A (es) |
HK (1) | HK1042096A1 (es) |
HN (1) | HN2000000019A (es) |
HR (1) | HRP20010574A2 (es) |
HU (1) | HUP0105231A3 (es) |
ID (1) | ID29584A (es) |
IL (1) | IL144307A0 (es) |
IS (1) | IS5997A (es) |
MA (1) | MA26718A1 (es) |
NO (1) | NO20013909L (es) |
OA (1) | OA11833A (es) |
PA (1) | PA8490601A1 (es) |
PE (1) | PE20001464A1 (es) |
PL (1) | PL349839A1 (es) |
SK (1) | SK11002001A3 (es) |
SV (1) | SV2001000020A (es) |
TN (1) | TNSN00028A1 (es) |
TR (2) | TR200201296T2 (es) |
WO (1) | WO2000047574A1 (es) |
ZA (1) | ZA200106520B (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL140721A0 (en) * | 1998-07-06 | 2002-02-10 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties |
HUP0105231A3 (en) * | 1999-02-11 | 2003-01-28 | Pfizer Prod Inc | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents and medicaments containing the compounds |
ATE260269T1 (de) | 1999-11-05 | 2004-03-15 | Cytovia Inc | Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung |
DE60008206T2 (de) * | 1999-11-30 | 2004-12-02 | Pfizer Products Inc., Groton | Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase |
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
EP1253921A4 (en) * | 2000-01-28 | 2004-10-13 | Merck & Co Inc | TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
US7173040B2 (en) | 2000-09-25 | 2007-02-06 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives |
EP1322644A1 (en) * | 2000-09-25 | 2003-07-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
US7053105B2 (en) | 2000-09-25 | 2006-05-30 | Janssen Pharmaceutica, N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
AU2002220559A1 (en) * | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
AU2001293847B2 (en) * | 2000-10-02 | 2007-05-24 | Janssen Pharmaceutica N.V. | Metabotropic glutamate receptor antagonists |
WO2002042296A1 (en) | 2000-11-21 | 2002-05-30 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting benzoheterocyclic derivatives |
ES2260316T3 (es) | 2000-12-27 | 2006-11-01 | Janssen Pharmaceutica N.V. | Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa. |
US20040067968A1 (en) * | 2000-12-27 | 2004-04-08 | Angibaud Patrick Rene | Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline |
US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
ATE450531T1 (de) * | 2001-05-16 | 2009-12-15 | Cytovia Inc | Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel |
EP1392283A4 (en) | 2001-05-16 | 2004-10-20 | Cytovia Inc | COUMARINS AND SUBSTITUTED QUINOLINES USED AS CASPASE ACTIVATORS |
US20030139332A1 (en) * | 2001-07-09 | 2003-07-24 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
ES2323265T3 (es) | 2001-12-19 | 2009-07-10 | Janssen Pharmaceutica Nv | Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa. |
WO2003080058A1 (en) * | 2002-03-22 | 2003-10-02 | Janssen Pharmaceutica. N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
CA2479109C (en) * | 2002-03-29 | 2011-08-02 | Janssen Pharmaceutica N.V. | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
ATE336496T1 (de) | 2002-04-15 | 2006-09-15 | Janssen Pharmaceutica Nv | Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen |
US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1509515A4 (en) | 2002-05-16 | 2006-07-05 | Cytovia Inc | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE |
US20040186160A1 (en) * | 2002-12-13 | 2004-09-23 | Sugen, Inc. | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors |
EP1585743B1 (en) * | 2002-12-19 | 2007-05-23 | Pfizer Inc. | 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
DK2476667T3 (da) | 2003-02-26 | 2014-09-15 | Sugen Inc | Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
TW200504057A (en) * | 2003-02-27 | 2005-02-01 | Chugai Pharmaceutical Co Ltd | Benzothiophene derivative |
CA2533626A1 (en) * | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
WO2005051392A1 (en) | 2003-11-20 | 2005-06-09 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use |
WO2005089502A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
EP1732549A4 (en) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089504A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
EP1740184A1 (en) * | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
KR100859891B1 (ko) | 2004-08-26 | 2008-09-23 | 화이자 인코포레이티드 | 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물 |
NZ552946A (en) * | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
BRPI0514687A (pt) * | 2004-08-26 | 2008-06-17 | Pfizer | compostos amino heteroarila como inibidores de proteìna tirosina cinase |
EP1807426A2 (en) * | 2004-10-07 | 2007-07-18 | Cytovia, Inc. | SUBSTITUTED N-ARYL-1H-PYRAZOLOÝ3,4-b¨QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS |
CA2617056A1 (en) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
PL2960253T3 (pl) | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
CA2634598A1 (en) * | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
BRPI0711358A2 (pt) | 2006-05-09 | 2011-09-27 | Pfizer Prod Inc | derivados do ácido cicloalquilamino e suas composições farmacêuticas |
NZ574580A (en) | 2006-08-21 | 2011-12-22 | Hoffmann La Roche | Her2 tumor therapy with an anti-vegf antibody |
RU2472788C9 (ru) * | 2007-05-23 | 2013-04-20 | Аллерган, Инк. | (бициклогетероарил)имидазолил)метилгетероарильные соединения как агонисты адренергических рецепторов |
PL2155733T3 (pl) * | 2007-05-23 | 2013-02-28 | Allergan Inc | Cykliczne laktamy do leczenia jaskry lub podwyższonego ciśnienia śródgałkowego |
US8129356B2 (en) * | 2007-10-01 | 2012-03-06 | Vanderbilt University | Bmx mediated signal transduction in irradiated vascular endothelium |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
EP2370436A1 (en) * | 2008-11-13 | 2011-10-05 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
CN102307875A (zh) | 2009-02-09 | 2012-01-04 | 苏伯俭股份有限公司 | 吡咯并嘧啶基axl激酶抑制剂 |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
TW201035088A (en) | 2009-02-27 | 2010-10-01 | Supergen Inc | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
HUE052198T2 (hu) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology Inc | Heterociklusos protein kináz inhibitorok |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
WO2014062655A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt |
AU2013331496B2 (en) | 2012-10-16 | 2017-07-27 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ROR-gamma-t |
KR20150070350A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | Ror-감마-t의 페닐 결합 퀴놀리닐 조절제 |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
KR102334260B1 (ko) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 및 alk2 억제제 및 이들의 사용 방법 |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
CA3006743A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
CN108003150A (zh) * | 2016-10-31 | 2018-05-08 | 河南工业大学 | 4-杂芳基喹啉酮衍生物的制备方法及其应用 |
KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2732531A1 (de) * | 1977-07-19 | 1979-02-01 | Hoechst Ag | Imidazolcarbonsaeuren und deren derivate |
US4835154A (en) * | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
US5053543A (en) * | 1990-11-28 | 1991-10-01 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
US5136085A (en) * | 1990-11-28 | 1992-08-04 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
AU711142B2 (en) * | 1995-12-08 | 1999-10-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives |
EP0988038B1 (en) * | 1997-06-02 | 2002-08-14 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
GEP20033001B (en) | 1998-08-27 | 2003-06-25 | Pfizer Prod Inc | Alkynyl-Substituted Quinolin-2-One Derivatives Useful As Anticancer Agents |
HUP0105231A3 (en) * | 1999-02-11 | 2003-01-28 | Pfizer Prod Inc | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents and medicaments containing the compounds |
-
2000
- 2000-02-04 HU HU0105231A patent/HUP0105231A3/hu unknown
- 2000-02-04 JP JP2000598494A patent/JP4090200B2/ja not_active Expired - Fee Related
- 2000-02-04 TR TR2002/01296T patent/TR200201296T2/xx unknown
- 2000-02-04 ES ES00901292T patent/ES2243228T3/es not_active Expired - Lifetime
- 2000-02-04 TR TR2002/01297T patent/TR200201297T2/xx unknown
- 2000-02-04 DE DE60020812T patent/DE60020812T2/de not_active Expired - Lifetime
- 2000-02-04 EE EEP200100425A patent/EE200100425A/xx unknown
- 2000-02-04 OA OA1200100212A patent/OA11833A/en unknown
- 2000-02-04 CA CA002362394A patent/CA2362394C/en not_active Expired - Fee Related
- 2000-02-04 WO PCT/IB2000/000121 patent/WO2000047574A1/en active IP Right Grant
- 2000-02-04 AU AU21248/00A patent/AU2124800A/en not_active Abandoned
- 2000-02-04 BR BR0008202-3A patent/BR0008202A/pt not_active IP Right Cessation
- 2000-02-04 EA EA200100766A patent/EA200100766A1/ru unknown
- 2000-02-04 CZ CZ20012910A patent/CZ20012910A3/cs unknown
- 2000-02-04 AP APAP/P/2001/002241A patent/AP2001002241A0/en unknown
- 2000-02-04 PL PL00349839A patent/PL349839A1/xx not_active Application Discontinuation
- 2000-02-04 EP EP00901292A patent/EP1150973B1/en not_active Expired - Lifetime
- 2000-02-04 KR KR1020017010187A patent/KR20010102073A/ko not_active Application Discontinuation
- 2000-02-04 ID IDW00200101724A patent/ID29584A/id unknown
- 2000-02-04 SK SK1100-2001A patent/SK11002001A3/sk unknown
- 2000-02-04 CN CN00803668A patent/CN1340051A/zh active Pending
- 2000-02-04 AT AT00901292T patent/ATE297916T1/de not_active IP Right Cessation
- 2000-02-04 IL IL14430700A patent/IL144307A0/xx unknown
- 2000-02-09 US US09/501,163 patent/US6258824B1/en not_active Expired - Fee Related
- 2000-02-09 MA MA25905A patent/MA26718A1/fr unknown
- 2000-02-09 CO CO00008430A patent/CO5140097A1/es unknown
- 2000-02-09 DZ DZ000021A patent/DZ3009A1/xx active
- 2000-02-09 HN HN2000000019A patent/HN2000000019A/es unknown
- 2000-02-09 TN TNTNSN00028A patent/TNSN00028A1/fr unknown
- 2000-02-10 PE PE2000000103A patent/PE20001464A1/es not_active Application Discontinuation
- 2000-02-10 AR ARP000100589A patent/AR028985A1/es not_active Application Discontinuation
- 2000-02-10 SV SV2000000020A patent/SV2001000020A/es not_active Application Discontinuation
- 2000-02-10 GT GT200000014A patent/GT200000014A/es unknown
- 2000-02-10 PA PA20008490601A patent/PA8490601A1/es unknown
-
2001
- 2001-04-17 US US09/836,026 patent/US6388092B2/en not_active Expired - Fee Related
- 2001-07-10 IS IS5997A patent/IS5997A/is unknown
- 2001-07-30 HR HR20010574A patent/HRP20010574A2/hr not_active Application Discontinuation
- 2001-08-08 ZA ZA200106520A patent/ZA200106520B/en unknown
- 2001-08-10 NO NO20013909A patent/NO20013909L/no not_active Application Discontinuation
- 2001-08-30 BG BG105860A patent/BG105860A/xx unknown
-
2002
- 2002-03-07 US US10/092,744 patent/US6710209B2/en not_active Expired - Fee Related
- 2002-05-31 HK HK02104118.7A patent/HK1042096A1/zh unknown
-
2004
- 2004-02-05 JP JP2004029709A patent/JP4216740B2/ja not_active Expired - Fee Related
- 2004-07-20 JP JP2004211298A patent/JP2005002124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5140097A1 (es) | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agnetes anticancerigenos | |
CO5130017A1 (es) | Derivados de quinolin-2-ona alquinil sustituidos utiles como agentes anticancerosos | |
CO5160273A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos derivados de quinazolina | |
AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
CO5080780A1 (es) | Derivado de amida y antagonista de nociceptina | |
AR036041A1 (es) | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen | |
CO4780025A1 (es) | Compuestos de triarilo | |
HRP20080064T3 (en) | Prodrugs of piperazine and substituted piperidine antiviral agents | |
RS53153B (en) | ANTAGONISTS OF HYSTAMINE -3 RECEPTORS | |
AR069637A1 (es) | Derivados de pirazinas | |
CO5290258A1 (es) | Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados | |
ES2570429T3 (es) | Inhibidores de heteroaril quinasa de anillo condensado | |
CO5261539A1 (es) | Compuestos farmaceuticamente activos | |
AR073586A1 (es) | Compuestos heterociclicos utiles para el tratamiento de vhc | |
ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
CO5150164A1 (es) | Derivados de pirazolopiridina | |
EA200600358A1 (ru) | Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2 | |
RS52222B (en) | STIRYLPYRIDINE DERIVATIVES AND THEIR USE FOR THE BINDING AND IMAGING OF AMYLOID PLACES | |
AR051469A1 (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
CO5150159A1 (es) | Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio | |
EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR039329A1 (es) | Derivados de triazol, antagonistas de receptor de taquicinina | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
AR056861A1 (es) | Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion |